Consumed content does not have a uuid. Unable to continue. -- Study reveals fresh insights into genetics of schizophrenia - Queensland Brain Institute - The University of Queensland, Australia

Status message

Consumed content does not have a uuid. ==
20 September 2011

Researchers are a step closer to unravelling the genetic underpinnings of schizophrenia following the largest genome-wide association study of the disorder ever undertaken.

Researchers are a step closer to unravelling the genetic underpinnings of schizophrenia following the largest genome-wide association study of the disorder ever undertaken.

An international consortium of 190 researchers from 135 institutions, including the Queensland Brain Institute (QBI), found significant associations with schizophrenia for five new and two previously-implicated locations on the human genome.

It’s long been recognised that schizophrenia is highly heritable.

However, this new study has pinpointed novel regions of the human genome significantly associated with disease, and confirmed other recently reported genomic regions that may harbour disease-causing genetic variation.

According to Professor Bryan Mowry from QBI, the Queensland Centre for Mental Health Research and UQ’s Department of Psychiatry, who initiated and coordinated the Australian contribution to this study, these findings were made possible because of the unprecedented size of the study, with more than 50,000 participants.

“It provides a solid foundation for beginning to understand the mechanisms underlying the substantial genetic predisposition to schizophrenia,” Professor Mowry said.

The research was published in the latest issue of Nature Genetics.

Schizophrenia affects 1 in 100 people and its onset is typically in adolescence or early adulthood.

Psychosis (comprising hallucinations and delusions) is the hallmark of schizophrenia, but other symptoms such as personal neglect and amotivation are common, as is an increased risk of suicide.

Professor Mowry says that gaining a better understanding of the genetic architecture of schizophrenia will ultimately aid the earlier diagnosis and management of the disorder.

“If your genetic profile suggests you have a predisposition towards developing schizophrenia, it will be particularly important for you to avoid known environmental risk factors – such as smoking cannabis,” he says.

“We also expect that understanding the biological mechanisms underlying the disorder will lead to more robust therapeutics in future.”

The strongest genome-wide association finding in the study was to single nucleotide polymorphisms (SNPs) in a region containing numerous immune-related genes, suggesting schizophrenia may be triggered by autoimmune responses or infection.

Another SNP in a region linked to neuronal development was also implicated, suggesting a novel mechanism underlying schizophrenia.

The study also confirmed genetic overlap between bipolar disorder and schizophrenia, suggesting that these disorders have shared rather than separate roots.

MEDIA CONTACT

Denise Cullen
Executive Communications Officer
Phone: +61 7 3346 6434
Email: d.cullen2@uq.edu.au

NOTES TO THE EDITOR:

Psychiatric Genomics Laboratory

The primary research goal of Professor Bryan Mowry’s laboratory is to identify and functionally characterise susceptibility genes for schizophrenia and related disorders using a combination of clinical, molecular and statistical genetic approaches. The laboratory also incorporates second generation sequencing in order to comprehensively investigate genetic variants and relevant gene expression to produce reliable candidates for functional validation.

Queensland Brain Institute

The Queensland Brain Institute (QBI) was established as a research institute of the University of Queensland in 2003. The Institute is now operating out of a new $63 million state-of-the-art facility and houses 33 principal investigators with strong international reputations. QBI is one of the largest neuroscience institutes in the world dedicated to understanding the mechanisms underlying brain function.

What is GWAS?

GWAS is the abbreviation for genome-wide association study. It consists of rapidly screening hundreds of thousands of DNA markers (single nucleotide polymorphisms, or SNPs) of known location on the human genome across thousands of DNA samples of people with a particular disease and thousands of healthy people (controls). The intended outcome is to discover genetic variations associated with disease, particularly common diseases such as asthma, cancer, diabetes, heart disease and mental illnesses.

What is a SNP?

SNPs are single nucleotide polymorphisms that are relatively evenly spaced across the human genome (approximately one every 80 bases) and are strategically selected to comprise a dense panel of markers of genetic variation for use in GWAS. If certain SNPs are associated with disease – that is, if they are significantly more frequent in disease cases than controls, they highlight a region of the genome where disease-causing variants may be located.